HANK Bioengineering

HANK Bioengineering is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the development of Natural Killer (NK) cell-based immunotherapies. The company utilizes its proprietary HANK (Highly Activated Natural Killer) cell technology to expand and activate NK cells for the treatment of various cancers and viral infections. Their approach focuses on both autologous and allogeneic cell products, aiming to enhance the body's innate immune response against malignant cells. HANK Bioengineering has advanced several programs into clinical trials, targeting solid tumors and hematological malignancies, and has also explored applications for infectious diseases like COVID-19. The company maintains its own research and manufacturing infrastructure to support its clinical development goals. Their technology is designed to produce high-purity NK cells with enhanced cytotoxicity and proliferative capacity.